COVID-19

Views & Analysis

MSD’s David Peacock on moving UK healthcare forward

David Peacock has worked across the world for MSD and other companies, and has now taken the helm of MSD’s UK & Ireland operations.

News

Controversy as pharma execs predict profits from COVID-19 va...

Concerns have emerged about access to some potential COVID-19 vaccines after pharma executives from three companies said they expect to make profits from their products in evidence to a US

News

Pandemic hits sales at Novartis after strong launch for SMA ...

The COVID-19 pandemic has bit into sales at Novartis, the big Swiss pharma said in second quarter results, after orders fell back following a period of stockpiling earlier in the year.

News

Blood sample with respiratory coronavirus positive

UK announces COVID-19 vaccine deals with BioNTech/Pfizer and...

The UK has secured 90 million doses of two different COVID-19 vaccines from BioNTech/Pfizer and Valneva, with an option of 40 million doses if they check out in trials.

News

Synairgen's inhaled drug cuts chances of COVID-19 progressin...

An inhaled drug developed by the UK firm Synairgen greatly reduces the chances of patients hospitalised with COVID-19 from progressing to more serious stages of the disease.

News

Call for COVID-19 'challenge trial' ahead of AstraZeneca vac...

Press reports suggest that there is good news about AstraZeneca and Oxford University’s COVID-19 vaccine due from an early stage trial in the coming days – but the focus is moving on how to

MSD’s David Peacock on moving UK healthcare forward

Controversy as pharma execs predict profits from COVID-19 va...

Pandemic hits sales at Novartis after strong launch for SMA ...

UK announces COVID-19 vaccine deals with BioNTech/Pfizer and...

Synairgen's inhaled drug cuts chances of COVID-19 progressin...

Call for COVID-19 'challenge trial' ahead of AstraZeneca vac...

AI-powered triage is coming to the NHS App

Discover a new era of healthcare panel engagement: Grounded ...

COVID-19

Editor's Picks